25.85 USD
+0.17 (+0.66%)
Taking everything into account, ASTH scores 4 out of 10 in our fundamental rating. ASTH was compared to 100 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of ASTH while its profitability can be described as average. ASTH is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
- ASTH had positive earnings in the past year.
- In the past year ASTH had a positive cash flow from operations.
- Each year in the past 5 years ASTH has been profitable.
- Each year in the past 5 years ASTH had a positive operating cash flow.
1.2 Ratios
- With a Return On Assets value of 0.43%, ASTH perfoms like the industry average, outperforming 51.00% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 1.23%, ASTH is in line with its industry, outperforming 56.00% of the companies in the same industry.
- ASTH has a Return On Invested Capital of 2.95%. This is comparable to the rest of the industry: ASTH outperforms 49.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 9.19%.
- The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.43% | ||
| ROE | 1.23% | ||
| ROIC | 2.95% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
- ASTH's Profit Margin of 0.33% is in line compared to the rest of the industry. ASTH outperforms 50.00% of its industry peers.
- ASTH's Profit Margin has declined in the last couple of years.
- With a Operating Margin value of 2.59%, ASTH perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
- In the last couple of years the Operating Margin of ASTH has declined.
- ASTH has a worse Gross Margin (10.25%) than 73.00% of its industry peers.
- ASTH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.59% | ||
| PM (TTM) | 0.33% | ||
| GM | 10.25% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for ASTH has been increased compared to 1 year ago.
- ASTH has a worse debt/assets ratio than last year.
2.2 Solvency
- ASTH has an Altman-Z score of 2.26. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
- ASTH has a Altman-Z score (2.26) which is in line with its industry peers.
- ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
- The Debt to FCF ratio of ASTH (10.83) is comparable to the rest of the industry.
- ASTH has a Debt/Equity ratio of 1.29. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 1.29, ASTH is doing worse than 65.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | 10.83 | ||
| Altman-Z | 2.26 |
ROIC/WACC0.33
WACC8.81%
2.3 Liquidity
- A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.40, ASTH perfoms like the industry average, outperforming 53.00% of the companies in the same industry.
- ASTH has a Quick Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
- ASTH has a Quick ratio of 1.40. This is comparable to the rest of the industry: ASTH outperforms 59.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 |
3. Growth
3.1 Past
- The earnings per share for ASTH have decreased strongly by -85.38% in the last year.
- Measured over the past years, ASTH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.19% on average per year.
- Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 68.17%.
- Measured over the past years, ASTH shows a very strong growth in Revenue. The Revenue has been growing by 38.01% on average per year.
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
3.2 Future
- The Earnings Per Share is expected to grow by 31.87% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 18.29% on average over the next years. This is quite good.
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 136.05, ASTH can be considered very expensive at the moment.
- ASTH's Price/Earnings ratio is in line with the industry average.
- When comparing the Price/Earnings ratio of ASTH to the average of the S&P500 Index (27.33), we can say ASTH is valued expensively.
- ASTH is valuated rather expensively with a Price/Forward Earnings ratio of 20.27.
- 63.00% of the companies in the same industry are more expensive than ASTH, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of ASTH to the average of the S&P500 Index (24.12), we can say ASTH is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.05 | ||
| Fwd PE | 20.27 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASTH.
- ASTH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 78.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.37 | ||
| EV/EBITDA | 16.63 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ASTH's earnings are expected to grow with 29.02% in the coming years.
PEG (NY)N/A
PEG (5Y)7.09
EPS Next 2Y19.69%
EPS Next 3Y29.02%
5. Dividend
5.1 Amount
- No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ASTH (1/15/2026, 3:39:55 PM)
25.85
+0.17 (+0.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners55.03%
Inst Owner ChangeN/A
Ins Owners9.86%
Ins Owner Change0.75%
Market Cap1.30B
Revenue(TTM)2.90B
Net Income(TTM)9.54M
Analysts84.71
Price Target38.42 (48.63%)
Short Float %7.63%
Short Ratio5.59
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.42%
PT rev (3m)-16.3%
EPS NQ rev (1m)-30.36%
EPS NQ rev (3m)-75.42%
EPS NY rev (1m)-16.19%
EPS NY rev (3m)-58.79%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)-1.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136.05 | ||
| Fwd PE | 20.27 | ||
| P/S | 0.45 | ||
| P/FCF | 13.37 | ||
| P/OCF | 12.17 | ||
| P/B | 1.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.63 |
EPS(TTM)0.19
EY0.74%
EPS(NY)1.27
Fwd EY4.93%
FCF(TTM)1.93
FCFY7.48%
OCF(TTM)2.12
OCFY8.22%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)N/A
PEG (5Y)7.09
Graham Number8.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.43% | ||
| ROE | 1.23% | ||
| ROCE | 4.68% | ||
| ROIC | 2.95% | ||
| ROICexc | 4.15% | ||
| ROICexgc | N/A | ||
| OM | 2.59% | ||
| PM (TTM) | 0.33% | ||
| GM | 10.25% | ||
| FCFM | 3.35% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | 10.83 | ||
| Debt/EBITDA | 8.9 | ||
| Cap/Depr | 25.55% | ||
| Cap/Sales | 0.33% | ||
| Interest Coverage | 2.01 | ||
| Cash Conversion | 94.59% | ||
| Profit Quality | 1016.69% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z | 2.26 |
F-Score3
WACC8.81%
ROIC/WACC0.33
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y45.68%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A
ASTRANA HEALTH INC / ASTH FAQ
Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?
ChartMill assigns a fundamental rating of 4 / 10 to ASTH.
What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Overvalued.
How profitable is ASTRANA HEALTH INC (ASTH) stock?
ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.
What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 136.05 and the Price/Book (PB) ratio is 1.67.
Can you provide the financial health for ASTH stock?
The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.